A pharmacotherapy of hyperlipidemia.

A Review of Pharmacotherapy for Coronavirus Disease 2019 (COVID-19)

The epidemic of COVID-19 and its associated acute respiratory syndrome has posed an unprecedented challenge in identifying effective drugs to prevent and treat it. Due to the high prevalence of this disease and the high number of people at risk, medical staff needs accurate evidence regarding effective drug treatments for this infection. There is currently no effective treatment for COVID-19. B...

Association of androgenetic alopecia and hyperlipidemia

Background an objective: Several studies have indicated that vertex type androgenetic alopecia have a higher-than-normal risk for coronary heart disease but few studies focused on lipid profiles which are important in the pathogenesis of coronary heart disease. This study was designed to investigate the relation between vertex type androgenetic alopecia (Grade III and higher according to ...

Cyclosporin A-Induced Hyperlipidemia

Cyclosporin A (CsA) is an immunosuppressant drug widely used in organ transplant recipients and patients with auto-immune disorders. Long-term treatment with CsA is associated with hyperlipidemia and an increased risk of atherosclerosis. The mechanisms by which cyclosporin A causes hyperlipidemia are unclear. Cell and animal studies have pointed to various mechanisms that may mediate CsA-induce...

P115: A Novel High Tech Approach to Monitor the Pharmacotherapy of Alzheimer; a Narrative Review

Alzheimer's disease (AD) is multisystem and multifactor disease with a long no-symptom stage. We propose that a more effective approach to use fMRI as a still emerging, repeatable, non- invasive neuroimaging tools that can be very useful for evaluating, diagnosis, treatment and drugs- development. We studied 30 articles which published between 2008-2017 that included the effects of different bi...

A Comparative Study on the Effectiveness of Garlic with Clofibrate in the Treatment of Hyperlipidemia